Aura Biosciences, Inc.
AURA is overvalued
NASDAQ · Healthcare
FAIR PRICE
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
$6.34
MARKET PRICE
$1.63
FAIR PRICE
$4.71
MARGIN
COMMUNITY BUY ZONE
UNLOCKS AT 10
Where does the market buy AURA?
No one has priced AURA yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.
COMMUNITY MEDIAN
▓▓▓▓▓
BUYERS AT TODAY'S PRICE
▓▓ %
0/10 INVESTORS · 10 MORE TO UNLOCK
METRICS
NOW AVAILABLE
Get notified when AURA's fair price changes
Push notifications when AURA's valuation shifts. Available on iOS and Android.
FPI RATING
Low debt levels and attractive valuation, but below-average fundamental quality and limited growth momentum.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$1.30
Fair price × 0.80
DISTANCE
79.4%
Price to entry level
At the current price of $6.34, AURA trades 79.4% above the conservative entry level of $1.30. This entry level represents a 20% margin of safety below the calculated fair price of $1.63 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate AURA's fair price
Aura Biosciences, Inc.'s fair price of $1.63 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $6.34, AURA trades 74.3% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting AURA's risk profile.
RELATIVE · 30%
Comparing AURA's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for AURA, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate AURA's fair value with your own inputs.
AURA DCF Calculator
Pre-filled with AURA's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter AURA's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of AURA's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare AURA against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for AURA.
Explore on BuliosFAQ
What is the fair price of AURA?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Aura Biosciences, Inc. is $1.63. At the current market price of $6.34, AURA trades 74.3% above its calculated fair value.
Is AURA overvalued or undervalued?+
Aura Biosciences, Inc. is currently overvalued based on our valuation model. The stock trades at $6.34, which is 74.3% above the fair price of $1.63.
What is the margin of safety for AURA?+
With a 20% margin of safety applied to the fair price of $1.63, the conservative entry level for AURA is $1.30. At the current market price of $6.34, the stock trades 79.4% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is AURA's fair price updated?+
We update fair price calculations for AURA daily after market close. The current fair price of $1.63 incorporates the latest market data and sector multiples.
What factors affect AURA's fair price calculation?+
AURA's fair price of $1.63 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -73.2%.
Is AURA a good buy right now?+
At $6.34, AURA trades 74.3% above our fair value estimate of $1.63. The stock is currently overvalued. ROE stands at -73.2% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does AURA pay dividends?+
AURA does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.